Adalimumab-associated optic neuritis

Jacob H. Chung, Gregory P. Van Stavern, Larry P. Frohman, Roger E. Turbin

Research output: Contribution to journalArticlepeer-review

84 Scopus citations


We present, to our knowledge, the first published cases of optic neuritis associated with adalimumab, a medication in the class of anti-tumor necrosis factor-alpha (TNF-α) antagonists. Approved in recent years by the FDA, adalimumab (Humira, Abbott Laboratories; Abbott Park, IL) is a recombinant monoclonal antibody that targets and blocks the physiologic effects of TNF. Other TNF antagonists have had associations with optic neuritis and demyelinating events.

Original languageEnglish
Pages (from-to)133-136
Number of pages4
JournalJournal of the Neurological Sciences
Issue number1-2
StatePublished - May 15 2006


  • Adalimumab
  • Enbrel
  • Etanercept
  • Humira
  • Infliximab
  • Optic neuritis
  • Remicade
  • Tumor necrosis factor


Dive into the research topics of 'Adalimumab-associated optic neuritis'. Together they form a unique fingerprint.

Cite this